Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Beraprost API Manufacturers & Suppliers
3 verified results
Commercial-scale Suppliers
All certificates
All certificates
Employees: +50
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Beraprost | CAS No: 88430-50-6 | GMP-certified suppliers
A medication that treats pulmonary hypertension by improving blood flow through vasodilation and antiplatelet effects, suitable for clinical development and vascular disease management.
Therapeutic categories
Primary indications
- For the treatment of pulmonary hypertension
Product Snapshot
- Beraprost is an oral small molecule formulated as coated and film-coated tablets
- It is indicated primarily for the treatment of pulmonary hypertension
- The product is currently in the investigational stage and has not received FDA or EMA approval
Clinical Overview
Pharmacodynamically, beraprost binds to prostacyclin membrane receptors on vascular smooth muscle cells, leading to inhibition of intracellular calcium release. This decrease in cytosolic calcium concentration results in smooth muscle relaxation and vasodilation, contributing to improved blood flow. Additionally, beraprost’s antiplatelet effects reduce platelet aggregation, which may provide protective effects in vascular disease.
Pharmacokinetic data indicate that beraprost is stable and orally bioavailable, which offers a practical advantage over intravenously administered prostacyclin therapies used in pulmonary arterial hypertension (PAH). Detailed absorption, distribution, metabolism, and excretion (ADME) parameters are limited; however, as a cytochrome P450 substrate, particularly involving CYP2C8, potential drug-drug interactions should be considered in clinical use.
Safety and toxicity profiles are generally favorable, with tolerability supported by clinical trials. Common adverse effects have not been extensively characterized in large populations. Given its investigational status, beraprost lacks widespread regulatory approval and established branded formulations internationally, with usage predominantly within clinical research settings.
For formulation scientists and API sourcing professionals, quality considerations should focus on the synthetic nature of beraprost requiring rigorous control of stereochemistry and purity to ensure consistent pharmacological activity. Supply chain verification of manufacturers’ compliance with Good Manufacturing Practice (GMP) and robust impurity profiling is essential to support clinical development and regulatory submission processes.
Identification & chemistry
| Generic name | Beraprost |
|---|---|
| Molecule type | Small molecule |
| CAS | 88430-50-6 |
| UNII | 35E3NJJ4O6 |
| DrugBank ID | DB05229 |
Pharmacology
| Summary | Beraprost is an orally active prostacyclin analogue that binds to prostacyclin receptors, leading to inhibition of intracellular calcium release and subsequent vascular smooth muscle relaxation. It exhibits vasodilatory, antiplatelet, and cytoprotective effects, primarily targeting pulmonary hypertension. Its pharmacodynamic profile supports modulation of vascular tone and platelet aggregation. |
|---|---|
| Mechanism of action | Beraprost acts by binding to prostacyclin membrane receptors ultimately inhibiting the release of Ca<sup>2+</sup> from intracellular storage sites. This reduction in the influx of Ca<sup>2+</sup> has been postulated to cause relaxation of the smooth muscle cells and vasodilation. |
| Pharmacodynamics | Beraprost is a stable, orally active prostacyclin analogue with vasodilatory, antiplatelet and cytoprotective effects. Beraprost is generally well tolerated and appears to be an effective agent in the treatment of patients with Buerger's disease and arteriosclerosis obliterans. Comparative data from a large randomised trial indicated that the drug appears as effective as ticlopidine in patients with these conditions. In patients with intermittent claudication, significant benefits of beraprost compared with placebo were reported in a randomised clinical trial; however, the use of beraprost in these patients is not supported by recent preliminary unpublished data from a large, phase III, placebo-controlled study. Limited data suggest some efficacy with long-term beraprost treatment of patients with PAH, where options are few and where oral administration of the drug could be a considerable advantage over intravenous prostacyclin (PGI2) therapy. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Prostacyclin receptor | Humans |
ADME / PK
| Absorption | Oral bioavailability is 50–70%. |
|---|---|
| Half-life | 35–40 minutes |
Formulation & handling
- Beraprost is a small molecule intended for oral administration in tablet form, including coated and film-coated variants.
- Due to its low water solubility and moderate lipophilicity (LogP 3.6), formulation strategies should enhance bioavailability.
- Concurrent use with anticoagulant or antiplatelet herbal supplements should be avoided to prevent potential pharmacodynamic interactions.
Regulatory status
Beraprost is a type of Prostaglandin Analogues
Prostaglandin analogues are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the field of medicine. These synthetic compounds mimic the effects of natural prostaglandins, which are hormone-like substances found in the body.
Prostaglandin analogues have gained significant attention in medical research due to their diverse therapeutic applications. They exhibit a wide range of physiological activities, such as regulating inflammation, blood flow, and hormone levels. These compounds are commonly used in the treatment of various conditions, including glaucoma, ocular hypertension, and certain types of cancer.
One notable application of prostaglandin analogues is in ophthalmology. These compounds effectively reduce intraocular pressure by increasing the outflow of aqueous humor, providing an effective treatment for glaucoma patients. Moreover, prostaglandin analogues offer the advantage of once-daily dosing, enhancing patient compliance and convenience.
In the field of oncology, prostaglandin analogues have shown promise as anticancer agents. They exert anti-proliferative effects on cancer cells and can induce apoptosis, making them valuable in the treatment of certain malignancies.
Overall, prostaglandin analogues represent a significant class of pharmaceutical APIs with diverse therapeutic applications. Continued research and development in this area hold great potential for the advancement of medicine and the improvement of patient care.
Beraprost (Prostaglandin Analogues), classified under Anti-inflammatory Agents
Anti-inflammatory agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used to treat various inflammatory conditions. These agents play a vital role in alleviating pain, reducing swelling, and controlling inflammation in the body. They are widely employed in the management of diverse medical conditions, including arthritis, autoimmune disorders, asthma, and skin conditions like dermatitis.
Anti-inflammatory APIs primarily function by inhibiting the production of specific enzymes called cyclooxygenases (COX) and lipoxygenases (LOX). These enzymes are responsible for the synthesis of pro-inflammatory molecules known as prostaglandins and leukotrienes, respectively. By suppressing the activity of COX and LOX, anti-inflammatory agents effectively curtail the production of these inflammatory mediators, thereby mitigating inflammation.
Common examples of anti-inflammatory APIs include non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, aspirin, and naproxen. These agents exhibit analgesic, antipyretic, and anti-inflammatory properties. Another group of anti-inflammatory APIs includes corticosteroids, such as prednisone and dexamethasone, which are synthetic hormones that modulate the body's immune response to control inflammation.
In conclusion, anti-inflammatory agents are a vital category of pharmaceutical APIs widely used to manage inflammation-related disorders. They target enzymes involved in the synthesis of pro-inflammatory molecules, effectively reducing pain and swelling. NSAIDs and corticosteroids are commonly prescribed anti-inflammatory APIs due to their efficacy in controlling inflammation.
Beraprost API manufacturers & distributors
Compare qualified Beraprost API suppliers worldwide. We currently have 3 companies offering Beraprost API, with manufacturing taking place in 3 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Chinoin | Producer | Hungary | Unknown | CoA, JDMF | 21 products |
| Chirogate International | Producer | Taiwan | Taiwan | CoA, FDA, GMP | 17 products |
| Yonsung Fine Chem. | Producer | South Korea | South Korea | CoA, JDMF | 13 products |
When sending a request, specify which Beraprost API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Beraprost API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
